US29970R2040 - ADR
EVAXION BIOTECH A/S
NASDAQ:EVAX (3/28/2024, 9:30:21 AM)
3
0 (0%)
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
EVAXION BIOTECH A/S
Bredgade 34E, Copenhagen K
COPENHAGEN 1260
CEO: Lars Staal Webner
Employees: 63
Website: https://www.evaxion-biotech.com/
EVAX stock results show that Evaxion Biotech met analyst estimates for earnings per share the fourth quarter of 2023.
COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
La plateforme AI-Immunology™ brevetée ouvre la voie d'une nouvelle ère dans le monde de la découverte, de la conception et du développement de vaccins...
Die unternehmenseigene AI-Immunology™-Plattform bietet das Potenzial für eine neue Ära der Entdeckung, des Designs und der Entwicklung von Impfstoffen...
Here you can normally see the latest stock twits on EVAX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: